Search Results
Your search for Colorectal matches 3163 pages
Showing 1051 - 1100Study Shows Aspirin Use Before Diagnosis May Lower Colorectal Cancer Mortality
A recent study found that long-term aspirin use before a diagnosis of colorectal cancer may be associated with lower colorectal cancer–specific mortality. The report, published by Figueiredo et al in JNCI: The Journal of the National Cancer Institute, suggests that the findings for prediagnosis...
Socially Distant Drive-by FluFIT Clinics May Increase Colorectal Cancer Screening Rates Among Black Patients During the COVID-19 Pandemic
Administering colorectal cancer screening kits through a socially distant drive-by flu vaccination clinic increased access to colorectal cancer screening among Black Americans, according to results presented by Washington et al at the AACR Virtual Meeting: COVID-19 and Cancer (Abstract S02-04)....
Impact of COVID-19 on Cancer Care Has Been ‘Profound,’ According to WHO
More than a year since the new coronavirus crisis began, its impact on cancer care has been stark, with “50% of governments (having) cancer services partially or completely disrupted because of the pandemic,” said André Ilbawi, MD, of the World Health Organization’s (WHO) Department of...
ASCO Names Advance of the Year: Molecular Profiling Drives Progress in Gastrointestinal Cancers
Molecular profiling allows clinicians to identify the molecular and genetic signatures that help to deliver treatments that are highly specific to a tumor. This tool has made possible a number of advances in the past year that are improving care for patients with gastrointestinal cancers. In...
Variation in Postoperative Mortality and Complications After Cancer Surgery Between High- vs Low- and Middle-Income Countries
In a prospective cohort study reported in The Lancet, Knight et al found that 30-day mortality after surgery for colorectal and gastric cancers was higher in low- and middle-income countries vs high-income countries (LMICs), with the difference only partly accounted for by patient or disease...
Hyperthermic Intraperitoneal Chemotherapy Plus Cytoreductive Surgery for Colorectal Cancer Metastases Does Not Improve Overall Survival
As reported in The Lancet Oncology by Quénet et al, the French phase III PRODIGE 7 trial has shown that the addition of hyperthermic intraperitoneal chemotherapy (HIPEC) to cytoreductive surgery did not improve overall survival—and was associated with an increase in postoperative late...
Adjuvant Doublet Chemotherapy for High-Risk Stage II Colorectal Cancer: 3- or 6- Month Duration?
In an analysis of data from the IDEA collaboration reported in the Journal of Clinical Oncology, Timothy J. Iveson, MD, FRCP, and colleagues found that 3 months (vs 6 months) of adjuvant CAPOX (capecitabine and oxaliplatin) may be a potential treatment option for patients with high-risk colorectal...
New Clinical Calculator May Predict Recurrence Risk After Curative Colectomy for Colon Cancer
As reported in the Journal of Clinical Oncology, Weiser et al have developed a "third-generation" clinical calculator at Memorial Sloan Kettering Cancer Center (MSK), which incorporates molecular and clinicopathologic characteristics and provides an accurate prediction of disease recurrence...
FDA Pipeline: Priority Reviews for Immunotherapies in Gastric Cancers, Anal Cancer
The U.S. Food and Drug Administration (FDA) recently granted Priority Review to nivolumab as either adjuvant or first-line therapy in several types of gastric cancers, as well as to a novel PD-1 inhibitor for locally advanced or metastatic squamous cell carcinoma of the anal canal. The FDA also...
Addition of Vemurafenib to Irinotecan/Cetuximab in Previously Treated Patients With BRAF V600E–Mutant Metastatic Colorectal Cancer
In a phase II trial (SWOG S1406) reported in the Journal of Clinical Oncology, Scott Kopetz, MD, PhD, and colleagues found that the addition of vemurafenib to irinotecan and cetuximab significantly improved progression-free survival in previously treated patients with BRAF V600E–mutant metastatic...
CDC Awards Huntsman Cancer Institute $3 Million to Improve Colorectal Cancer Screening
Huntsman Cancer Institute (HCI) at the University of Utah has been awarded a 5-year, $3 million grant from the Centers for Disease Control and Prevention (CDC) to improve Utah’s colorectal cancer screening rates. The program will build on an ongoing partnership between HCI’s Center for Health...
Duration of Adjuvant Chemotherapy Assessed in Stage III Colon Cancer
As reported in The Lancet Oncology by Thierry André, MD, of Sorbonne Université and Hôpital Saint Antoine, Paris, and colleagues, the prospective pooled analysis of six phase III trials in the IDEA collaboration has shown that noninferiority in overall survival for 3 vs 6 months of adjuvant...
High Recurrence-Free Survival Rates in Rectal Cancer After Clinical Complete Response to Neoadjuvant Chemoradiotherapy
In a study reported in The Lancet Oncology, Laura M. Fernandez, MD, of Champalimaud Foundation, Lisbon, and colleagues found high rates of conditional recurrence-free survival during watch-and-wait surveillance among patients with rectal cancer who maintained a clinical complete response to...
Indian Surgical Oncologist Offers Insights Into Delivering Equitable Cancer Care in a Resource-Challenged Country
The ASCO Post is pleased to introduce this department on Global Health-Care Equity. On an occasional basis, we will publish interviews between Guest Editor, Chandrakanth Are, MBBS, MBA, FRCS, FACS, and another oncologist or cancer care specialist spanning regions around the world. Our goal is to...
Thierry André, MD, on Mismatch Repair–Deficient Solid Cancers: Safety and Efficacy of Dostarlimab
Thierry André, MD, of Hôpital Saint-Antoine, discusses results from the GARNET study, which showed that dostarlimab, an anti–PD-1 antibody, demonstrated durable antitumor activity in patients with mismatch repair–deficient colorectal and noncolorectal solid tumors. No new safety signals were...
Tenna V. Henriksen, PhD Candidate, on Colorectal Cancer: Circulating Tumor DNA Analysis to Improve Treatment
Tenna V. Henriksen, PhD Candidate, of Aarhus University, discusses her findings on how circulating tumor DNA may help assess recurrence risk and the benefit of adjuvant therapy, and more quickly detect early relapse after treatment in patients with colorectal cancer (Abstract 11).
Empowering the FDA to Require Dose Optimization of All New Oncology Drugs
The vast majority of drugs used outside of oncology are evaluated in randomized dose-ranging trials to optimize the therapeutic index prior to the pivotal phase III trial. No one would think of dosing a statin or an antibiotic at the highest dose patients could tolerate, especially if that dose...
Cancer-Related Suicide Has Declined in the United States Over the Past 2 Decades
Despite increases in overall suicide rates in the United States during the past 2 decades, cancer-related suicides declined by 2.8% per year in the same time period, according to a new study published by Han et al in JNCI: Journal of the National Cancer Institute. The study found that the largest...
Prevalence of KRAS G12C Somatic Mutations by Cancer Type, Race, and Sex
In a study reported in a letter to the editor in The New England Journal of Medicine, Nassar et al identified the prevalence of the formerly “undruggable” KRAS G12C mutation across tumor types, race, and sex. As stated by the investigators, a recently reported early-phase clinical trial has shown...
Anti–PD-1 Therapy Dostarlimab for dMMR Gastrointestinal Cancers: Safety and Efficacy Examined
Dostarlimab, a monoclonal antibody targeting PD-1, showed strong and durable antitumor activity in patients with mismatch repair–deficient (dMMR) gastrointestinal tumors in the phase I GARNET study, reported Thierry André, MD, of Sorbonne Université and Hôpital Saint Antoine, Paris, and colleagues...
Performing Mammograms for Targeted Hospitalized Patients
Completing cancer screening tests such as mammograms can be challenging for low-income patients who may face such issues as lack of transportation or inability to take time off work. A team at Massachusetts General Hospital explored the possibility of addressing preventive care needs when patients...
Electronic Patient Self-Reporting of Adverse Events During Cancer Chemotherapy: eRAPID System
In a single-institution phase III trial reported in the Journal of Clinical Oncology, Absolom et al found that use of the electronic patient self-reporting of adverse events: patient information and advice (eRAPID) system was associated with improvements in patient-reported outcomes vs usual care...
Kai-Keen Shiu, MD, PhD, on Colorectal Cancer: Pembrolizumab vs Chemotherapy for Microsatellite Instability–High Disease
Kai-Keen Shiu, MD, PhD, of the University College Hospital NHS Foundation Trust - London, discusses an interim analysis of PFS 2 results (defined as time from random assignment to progression on the next line of therapy or death) from the phase III KEYNOTE-177 trial. This study has already shown...
Romain Cohen, MD, PhD, on Colon Cancer: Prognostic Value of Tumor Deposits
Romain Cohen, MD, PhD, of the Mayo Clinic and Sorbonne University, discusses a post-hoc analysis of phase III results from the CALGB/SWOG 80702 study, which showed that adding the number of tumor deposits, a negative prognostic factor, to the count of lymph node metastases may improve the accuracy...
Postsurgical Disease Recurrence in Stage I to III Colorectal Cancer May Be Predicted by ctDNA
Patients with stage I to III colorectal cancer and a high risk for disease recurrence may be identified by serial testing of circulating tumor DNA (ctDNA) after resection, according to a study in which ctDNA was more reliable than carcinoembryonic antigen (CEA) surveillance or standard radiologic...
Study Finds Artificial Intelligence May Help to Identify New Risk Factors for Early-Onset Colorectal Cancer
Electronic health record–based artificial intelligence may help uncover new risk factors in the development of early-onset colorectal cancer, according to study findings presented by Parker et al at the AACR Virtual Special Conference: Artificial Intelligence, Diagnosis, and Imaging (Abstract...
Adding Oxaliplatin to Fluoropyrimidine for Patients With Stage III Colon Cancer and Microsatellite Instability
In a pooled analysis reported in the Journal of Clinical Oncology, Cohen et al found that the addition of oxaliplatin to fluoropyrimidine was associated with improved overall and disease-free survival in patients with stage III colon cancer with microsatellite instability (MSI). They also found the ...
Rates of Eligible People Missing Timely Cancer Screenings: A Canadian Analysis
New research published by Abdel-Rahman in JNCCN—Journal of the National Comprehensive Cancer Network found more than one-third of eligible people miss timely screening tests for colorectal cancer, and at least one-quarter appear to miss timely screening tests for breast and cervical cancers....
Record Drop in Cancer Mortality for Second Straight Year Due to Improved Lung Cancer Treatment Reported in ‘Cancer Statistics, 2021’
Overall cancer death rates in the United States dropped continuously from 1991 through 2018, for a total decrease of 31%, including a 2.4% decline from 2017 to 2018. These findings were reported in the American Cancer Society’s “Cancer Statistics, 2021” article, published by Rebecca L. Siegel, MPH, ...
Stereotactic Ablative Body Radiotherapy in Extracranial Oligometastatic Cancers
In a registry-based observational study reported in The Lancet Oncology, Chalkidou et al found that stereotactic ablative body radiotherapy (SABR) was associated with high overall survival and low rates of toxicity in patients with extracranial oligometastatic cancers. Study Details The prospective ...
IDEA Collaboration: 3 vs 6 Months of Adjuvant Chemotherapy for Patients With Advanced Colon Cancer
This week, we’ll review a meta-analysis of several trials studying the efficacy of 3 vs 6 months of adjuvant chemotherapy for patients with advanced colon cancer. We’ll also discuss a report on the frequency of osteonecrosis of the jaw among patients with metastatic bone disease treated with...
FDA Pipeline: Two Reviews in NSCLC, Plus Prescribing Information Update for Darolutamide
Recently, the U.S. Food and Drug Administration (FDA) granted Priority Review to lorlatinib in ALK-positive non–small cell lung cancer (NSCLC) and Breakthrough Therapy designation to the combination of tiragolumab plus atezolizumab in NSCLC with high PD-L1 expression. The FDA also updated the...
Total Neoadjuvant Therapy vs Standard Therapy for Locally Advanced Rectal Cancer
In a systematic review and meta-analysis reported in JAMA Network Open, Kasi et al found that total neoadjuvant therapy was associated with improved pathologic complete response rates vs standard therapy with neoadjuvant concurrent chemoradiotherapy plus adjuvant chemotherapy in patients with...
Do Adult-Onset Cancer Survivors Have a Higher Risk of Developing a Subsequent Malignancy?
A study published by Hyuna Sung, PhD, and colleagues in JAMA found that adult-onset cancer survivors may have a greater risk of developing and dying from subsequent primary cancers than the general population. Cancers associated with smoking or obesity accounted for a majority of subsequent primary ...
Final Overall Survival Results of the IDEA Collaboration: 3 vs 6 Months of Adjuvant Chemotherapy for Stage III Colon Cancer
Thierry André, MD, and colleagues reported the prospective pooled analysis of six phase III trials in the IDEA collaboration in The Lancet Oncology. The analysis showed that noninferiority in overall survival for 3 vs 6 months of adjuvant chemotherapy was not established in patients with stage III...
GLOBOCAN 2020 Database Provides Latest Global Data on Cancer Burden, Cancer Deaths
On December 15, the International Agency for Research on Cancer (IARC) released the latest estimates on the global burden of cancer. The GLOBOCAN 2020 database, accessible online as part of the IARC Global Cancer Observatory, provides estimates of incidence and mortality in 185 countries for 36...
Risk of COVID-19 Infection in Patients With Cancer: Effect of Time of Diagnosis and Race
In a study reported in JAMA Oncology, Wang et al found that patients with cancer were at a greater risk of being infected with COVID-19 and having worse outcomes vs patients without cancer. Risk was greatest among patients with a more recent diagnosis and was even further exacerbated among Black...
Reducing Disparities in Cancer Care for Sexual and Gender Minority Patients
Although efforts have been made by various medical societies, including ASCO, over the past decade to address the needs of sexual and gender minorities in the cancer care setting, research shows that lesbian, gay, bisexual, transgender, and queer/questioning (LGBTQ) patients continue to face...
Intensity of Active Surveillance in Patients With Rectal Cancer Managed With a Watch-and-Wait Approach
In a study reported in The Lancet Oncology, Fernandez et al found high rates of conditional recurrence-free survival during watch-and-wait surveillance among patients with rectal cancer who maintained clinical complete response to neoadjuvant chemotherapy for 1, 3, or 5 years. Study Details In the...
Northwell Invests $6M in Comprehensive Cancer Center in Riverhead, New York
Northwell Health recently announced that it will open a $6.2 million, 11,300-square-foot comprehensive cancer center in Riverhead, New York, by the end of this year. The new facility will provide residents of the East End of Long Island access to integrated cancer services in a conveniently located ...
Expert Point of View: Cathy Eng, MD
Cathy Eng, MD, the David H. Johnson Chair in Surgical and Medical Oncology, Co-Leader of the Gastrointestinal (GI) Cancer Research Program, and Co-Director of GI Oncology at Vanderbilt-Ingram Cancer Center in Nashville, as well as Vice Chair of the SWOG GI Committee, said she found the study’s...
Study Reports Highly Skilled Surgeons Significantly Reduce Death From Colon Cancer
To improve long-term survival odds, individuals with early-stage colon cancer should have their surgery performed by highly skilled surgeons. In a study that used video assessment, surgeons with highly ranked skills gave their patients a 69% lower risk of dying at 5 years as compared with their...
Pembrolizumab Improves Progression-Free Survival vs Chemotherapy in First-Line Treatment of Microsatellite Instability–High Advanced Colorectal Cancer
As reported in The New England Journal of Medicine by Thierry André, MD, of Sorbonne Université and Hôpital Saint Antoine, Paris, and colleagues, the second interim analysis of the phase III KEYNOTE-177 trial has shown significantly prolonged progression-free survival with pembrolizumab vs...
Edith Mitchell, MD, Elected to Fellowship in the Royal College of Physicians of London
Edith P. Mitchell, MD, FACP, FCPP, FRCP, Associate Director for Diversity Affairs at the Sidney Kimmel Cancer Center–Jefferson Health, has been recognized as a fellow of the Royal College of Physicians of London (RCP). The RCP was founded in 1518 by a Royal Charter from King Henry VIII. RCP...
My Life of Service to Other Cancer Survivors
Six months before my diagnosis of metastatic colorectal cancer, in 2016, at age 38, I told my mom, “I feel like I’m dying.” Even though more than 10 specialists I had seen over the previous 8 years for unexplained bouts of abdominal pain and bloating, fatigue, and constipation kept assuring me that ...
2020 FDA Approvals of Drugs for Cancer Treatment
Over the past year (January to December 2020), the U.S. Food and Drug Administration (FDA) granted approval to several novel drugs and new indications for older therapeutic agents used in oncology and hematology. A brief review of new approvals appears here. For complete prescribing information for ...
Radiotherapy and Chemotherapy Before Total Mesorectal Excision for Locally Advanced Rectal Cancer: Comparison of Regimens
As reported in The Lancet Oncology by Bahadoer et al, the phase III RAPIDO trial has shown improved 3-year disease-related treatment failure with preoperative short-course radiotherapy followed by chemotherapy and total mesorectal excision (TME) vs preoperative chemoradiotherapy, TME, and optional...
Pembrolizumab vs Chemotherapy in First-Line Treatment of Microsatellite Instability–High Advanced Colorectal Cancer: KEYNOTE-177 Trial
As reported in The New England Journal of Medicine, the second interim analysis of the phase III KEYNOTE-177 trial has shown significantly prolonged progression-free survival with pembrolizumab vs fluorouracil (5-FU)-based chemotherapy as first-line treatment of patients with advanced...
The Problem of Heterogeneity Within Stage
The more senior of this duo grew up with prognostication by disease stage and was taught that all stage IV cancers behaved the same. In the past 3 decades, we have become much more cognizant of the heterogeneity in outcome within stage. Individual Kaplan-Meier plots by stage separate well but hide...
Staying a Step Ahead of Cancer
When I was diagnosed with metastatic breast cancer in 2018, my first thought was, I hope my three young children do not lose two parents to cancer. My husband, Ricky, had survived two bouts of cancer, early-stage colorectal cancer and, most recently, stage I kidney cancer. Like Ricky’s two...
